<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584556</url>
  </required_header>
  <id_info>
    <org_study_id>TA-C/hcc</org_study_id>
    <nct_id>NCT02584556</nct_id>
  </id_info>
  <brief_title>Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma</brief_title>
  <official_title>A Randomized Controlled Trial of Radical Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine that adjuvant systemic chemotherapy is superior to
      adjuvant transcatheter arterial chemoembolization(TACE) in prolonging recurrence free
      survival（RFS） in patients after radical resection of hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence free survival</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 months and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence</measure>
    <time_frame>6 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrence within liver</measure>
    <time_frame>3 months and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of tumor distant metastasis</measure>
    <time_frame>3 months and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>systemic chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks within 4-6 weeks after hepatic resection(a total of 4 cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcatheter Arterial Chemoembolization (Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou)) within 4-6 weeks after hepatic resection(a total of 1 cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>systemic chemotherapy</intervention_name>
    <description>Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.</description>
    <arm_group_label>systemic chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transcatheter Arterial Chemoembolization</intervention_name>
    <description>Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.</description>
    <arm_group_label>Transcatheter Arterial Chemoembolization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. a preoperative diagnosis of HCC with no previous treatment;

          2. compensated cirrhosis with Child-Pugh class A, B or no cirrhosis;

          3. multiple tumors more than 5 cm or tumor involving a major branch (the Wrstor second
             branch) of the portal or hepatic vein(s) on preoperative investigations, and on
             intraoperative ultrasonography and gross examination of the liver during operation;

          4. on exploration and intraoperative ultrasonography, the tumor with multiple lesions
             localized in right or left hemiliver,or the main tumor localized in one lobe only with
             a small solitary lesion in contralateral lobe, or tumor involving a major branch (the
             Wrst or second branch) of the portal or hepatic vein(s), which could be safely
             resected without grossly remaining tumors, and the patient was judged to have well
             preserved liver function to survive the operation.

          5. Adequate organ and marrow function, with neutrophil count≥1.5X10e9/L, platelet
             count≥75×10e9/L, AST or ALT﹤2.5×upper limit of normal (ULN), total bilirubin＜1.5×ULN,
             international normalized ratio ＜1.5;normal baseline left ventricular ejection
             fraction_lower limit of normal for the institution. Patients with AST and ALT＜5 ×ULN
             could be recruited if total bilirubin was in the normal range.

        Exclusion Criteria:

          1. documented allergy to study drugs; any previous TACE or systemic chemotherapy
             treatment before random assignment;

          2. concomitant use of any other anticancer therapy, including interferon alfa and herbal
             medicine approved by the local authority to be used as anticancer medicine (except
             palliative radiotherapy to a nontarget lesion);

          3. CNS metastasis;

          4. Other serious illness or medical condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lequn Li, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Affiliated Tumor Hospital, Guangxi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chengcheng Liao, MD</last_name>
    <email>148804@qq.com</email>
  </overall_contact>
  <reference>
    <citation>Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009 Oct;135(10):1437-45. doi: 10.1007/s00432-009-0588-2. Epub 2009 May 1.</citation>
    <PMID>19408012</PMID>
  </reference>
  <reference>
    <citation>Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg. 2009 Sep;198(3):313-8. doi: 10.1016/j.amjsurg.2008.09.026. Epub 2009 Mar 12.</citation>
    <PMID>19285298</PMID>
  </reference>
  <reference>
    <citation>Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.</citation>
    <PMID>23980077</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>October 21, 2015</last_update_submitted>
  <last_update_submitted_qc>October 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Chengcheng Liao</investigator_full_name>
    <investigator_title>Director, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

